Cancer
Skin Carcinoma
CI-CAN-00001511Explore in graph →
Top-level127 active trials2 approved drugs4 evidence items
- NCIt
- C4914
- ICD-10
- C44
- MeSH
- D000099313
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001511Explore in graph →
Clinical trials
389 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (52)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06150144 | The Efficacy and Safety of Using Intralesional 5-fluorouracil for Basal Cell Carcinoma | unknown | Phase 3 | 40 | University of AleppoOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT02324608 | Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer | completed | N/A | 15 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT05794035 |
| Impact of Hypofractionated Radiotherapy Strategy After Surgery of Skin Carcinomas in Older Patients(IMPACTE-01) |
| recruiting |
| N/A |
| 303 |
| Assistance Publique - Hôpitaux de ParisOTHER |
| 1 |
| Nov 30, 2023 |
| clinicaltrials |
| NCT05490485 | Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma | unknown | Phase 2 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Nov 8, 2023 | clinicaltrials |
| NCT04362722 | Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients(DUNCAN) | unknown | Phase 2 | 40 | Philogen S.p.A.INDUSTRY | 3 | Oct 10, 2023 | clinicaltrials |
| NCT05932511 | Topical Ascorbic Acid for Treatment of Squamous Cell Skin Cancer | unknown | Early Phase 1 | 15 | Center for Biomedical Research, Inc.INDUSTRY | 1 | Aug 30, 2023 | clinicaltrials |
| NCT05845632 | Time to Treatment and Disease-free Survival of Patients With High-risk Head-neck Cutaneous Squamous Cell Carcinoma | unknown | — | 965 | Maastricht University Medical CenterOTHER | 1 | Aug 16, 2023 | clinicaltrials |
| NCT05729139 | Cemiplimab/Peg-Interferon-α in Advanced CSCC | withdrawn | Phase 1 | 0 | Baptist Health South FloridaOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05886140 | Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin | unknown | N/A | 24 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 8, 2023 | clinicaltrials |
| NCT04456140 | Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study | completed | Phase 1 | 230 | Mayo ClinicOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT05493826 | Real World Study on the Use of Cemiplimab in Adult Patients in UK(REACT-CEMI) | completed | — | 110 | SanofiINDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT04252612 | Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study | withdrawn | Early Phase 1 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT03982212 | A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors | unknown | Phase 1 | 10 | University of Kansas Medical CenterOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT05842421 | Imaging Methods for the Diagnosis of Non-melanoma Skin Cancer and Its Precursors | completed | N/A | 250 | Technische Universität DresdenOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT00392561 | Bangladesh Vitamin E and Selenium Trial(BEST) | completed | N/A | 7,000 | University of ChicagoOTHER | 1 | Apr 26, 2023 | clinicaltrials |
| NCT05220748 | RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC | withdrawn | Phase 1 | 0 | Rakuten Medical, Inc.INDUSTRY | 0 | Apr 19, 2023 | clinicaltrials |
| NCT03769285 | Skin Cancer Prevention With Nicotinamide in Transplant Recipients - Pilot Trial(SPRINTR-Pilot) | unknown | Phase 2 | 120 | Women's College HospitalOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT03630601 | Photoacoustic Imaging in Diagnosing Changes in Tumors in Participants With Breast Cancer, Sarcoma, Skin Cancer, or Soft Tissue Malignancy and Healthy Volunteers | terminated | N/A | 7 | Roswell Park Cancer InstituteOTHER | 1 | Mar 31, 2023 | clinicaltrials |
| NCT04611321 | Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 15 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Mar 28, 2023 | clinicaltrials |
| NCT01662713 | Optical Frequency Domain Imaging for Non-melanoma Skin Cancers(OFDI) | completed | N/A | 10 | Massachusetts General HospitalOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT02941900 | Interest and Impact of Skin Cancer Genetic Testing | completed | — | 53 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT04918381 | CellFX Treat & Resect Low-Risk BCC Feasibility Study | completed | N/A | 30 | Pulse Biosciences, Inc.INDUSTRY | 1 | Jan 11, 2023 | clinicaltrials |
| NCT03775525 | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer(GEN602) | unknown | Phase 1 | 127 | Genzada Pharmaceuticals USA, Inc.INDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05628714 | A Patient Decision Aid for Patients With Superficial Basal Cell Carcinoma | completed | — | 222 | Maastricht University Medical CenterOTHER | 1 | Nov 29, 2022 | clinicaltrials |
| NCT03457766 | Presurgical Evaluation of Skin Cancers Using HIFU | completed | N/A | 40 | Assiut UniversityOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT04242173 | Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC | terminated | Phase 2 | 3 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT05602792 | A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 233 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT02218164 | Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma | completed | Phase 2 | 8 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT05550766 | Prognostic Value of RXR-α in Cutaneous Squamous and Basal Cell Carcinoma | unknown | — | 50 | Sohag UniversityOTHER | 0 | Sep 22, 2022 | clinicaltrials |
| NCT04985825 | Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma(I-PACE) | withdrawn | Phase 2 | 0 | Pega-One S.A.S.INDUSTRY | 0 | Sep 13, 2022 | clinicaltrials |
| NCT05025813 | Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma(DESQUAMATE) | recruiting | Phase 2 | 27 | Queensland HealthOTHER_GOV | 1 | Aug 1, 2022 | clinicaltrials |
| NCT00470496 | Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer | completed | Phase 1 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | terminated | Phase 1 | 49 | Genocea Biosciences, Inc.INDUSTRY | 1 | Jul 15, 2022 | clinicaltrials |
| NCT05238363 | The Efficacy and Safety of HLX07 in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC) | unknown | Phase 2 | 20 | Shanghai Henlius BiotechINDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT04116983 | DERM NMSC Validation Study | completed | — | 572 | Skin Analytics LimitedINDUSTRY | 1 | May 18, 2022 | clinicaltrials |
| NCT05315128 | Intralesional Versus Intramuscular Methotrexate for Non-melanoma Skin Cancers | completed | Phase 2 | 60 | Zagazig UniversityOTHER_GOV | 1 | Apr 7, 2022 | clinicaltrials |
| NCT04664582 | Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck | unknown | N/A | 100 | Jewish General HospitalOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT03458117 | T-VEC in Non-melanoma Skin Cancer(20139157 T-VEC) | completed | Phase 1 | 26 | University of ZurichOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT05246228 | Immune System Modulation and Outcome in High-risk cSCC Treated With Surgery and Radiotherapy(HR-cSCC) | unknown | — | 42 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 0 | Feb 18, 2022 | clinicaltrials |
| NCT05157763 | A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 32 | MediWound LtdINDUSTRY | 1 | Dec 15, 2021 | clinicaltrials |
| NCT00518037 | Quality of Life in Patients With Nonmelanoma Skin Cancer | completed | — | 112 | Northwestern UniversityOTHER | 1 | Dec 6, 2021 | clinicaltrials |
| NCT03291002 | Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC | unknown | Phase 1 | 98 | CureVacINDUSTRY | 5 | Nov 4, 2021 | clinicaltrials |
| NCT02751151 | Photodynamic Therapy for Prevention of Nonmelanoma Skin Cancer in Organ Transplant Recipients(PDT) | completed | N/A | 10 | Inova Health Care ServicesOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT02242929 | Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma(SCIN) | unknown | Phase 3 | 145 | Maastricht University Medical CenterOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT04123678 | DERM Health Economics Study | completed | — | 700 | Skin Analytics LimitedINDUSTRY | 1 | Aug 13, 2021 | clinicaltrials |
| NCT03180528 | Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer | completed | Phase 2 | 30 | Kavita SarinOTHER | 1 | Jun 8, 2021 | clinicaltrials |
| NCT04681456 | Skin Cancer Oncology Radiation Evidence Registry(SCORER) | terminated | — | 350 | GenesisCare USAOTHER | 1 | May 14, 2021 | clinicaltrials |
| NCT03773744 | MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma(Pelican) | withdrawn | Phase 1 | 0 | Turnstone Biologics, Corp.INDUSTRY | 0 | Apr 6, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jan 2, 2024source: clinicaltrials